Ocugen, Inc. (OCGN) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated April 14, 2021, covers the results of a Reconvened Special Meeting of Stockholders held by Ocugen, Inc. The meeting was originally scheduled for March 16, 2021, but was adjourned to April 14, 2021, specifically to allow additional time for stockholders to consider a proposal to amend the Company's Certificate of Incorporation.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results rather than financial performance.
Material Changes
The primary material change reported is the successful approval by stockholders to increase the number of authorized shares of Common Stock. The authorized share count was increased from 200 million to 295 million shares.
Voting Results and Management Commentary
At the Reconvened Meeting, 114,987,509 shares (61.15% of outstanding shares as of the February 11, 2021 record date) were represented. The voting results for the proposal to increase authorized shares were as follows:
- Votes For: 95,137,415
- Votes Against: 18,977,400
- Abstentions: 872,694
The proposal was approved. No other guidance, outlook, risks, or contingencies were disclosed in this specific filing.
Key Facts for Investor Verification
- Stockholders approved an increase in authorized common stock from 200 million to 295 million shares.
- The vote passed with approximately 83% of votes cast in favor (excluding abstentions).
- The meeting was reconvened from March 16, 2021, to April 14, 2021, solely for this proposal.
- This filing contains no financial data; investors should refer to the most recent 10-Q or 10-K for financial metrics.